focus -WSS

focus

author：explore 2025-09-27 06:03:14 - browse：235

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： NFL doctors' conflicts of interest could endanger players, report says

hotspot

leisure time

WSS

Robert F. Kennedy is pitching centrism on health, even on abortion

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Tuberculosis patients need more than just free medication

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

leisure time

focus

focus

Drug repurposing or repositioning? The language matters

KalVista pill reduced swelling 'attacks' caused by genetic disease

Heart attack and stroke risk calculators need revising

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

In age of alternative facts, a scholarly course on calling out crap

Google's generative AI to analyze medical images — and talk to docs

The cancer drug shortage isn’t new — and neither are the solutions

NFL doctors' conflicts of interest could endanger players, report says

Apple is now the first public company to be valued at $3 trillion

Paxlovid rebound happens. Why and to whom are still a mystery

knowledge

With heat waves through August, officials warn of health risks

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Kansas bar where gunfire wounded 9 last month closes permanently

Readout LOUD podcast: How biotech is using artificial intelligence

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

NFL doctors' conflicts of interest could endanger players, report says

Wikipedia

hotspot

leisure time

explore